Search research articles
Contact Us
Filters
Showing results (11-20 of 46) with videos related to
Page
of 5
Sort By:
Molecular Cancer Therapeutics
|
November 8, 2014
Repurposing the antihelmintic mebendazole as a hedgehog inhibitor
Andrew R Larsen, Ren-Yuan Bai, Jon H Chung, et al.
JCO Precision Oncology
|
February 17, 2022
Biallelic Deletion of <i>PALB2</i> Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition
Munveer S Bhangoo, Carrie Costantini, Brian T Clifford, et al.
European Urology
|
April 25, 2018
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
Sumanta K Pal, Paulo Bergerot, Nazli Dizman, et al.
European Urology
|
September 24, 2018
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
Andrea Necchi, Patrizia Giannatempo, Daniele Raggi, et al.
The Oncologist
|
July 12, 2019
Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype
Ethan S Sokol, Dean Pavlick, Garrett M Frampton, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 22, 2020
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling
Russell Madison, Alexa B Schrock, Emily Castellanos, et al.
European Urology Focus
|
August 31, 2020
Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma
Andrea Necchi, Russell Madison, Sumanta K Pal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2021
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Jessica K Lee, Mehlika Hazar-Rethinam, Brennan Decker, et al.
Case Reports in Oncology
|
November 20, 2014
A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
Jon H Chung, Siraj M Ali, Jenni Davis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 7, 2017
Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma
Aatur D Singhi, Siraj M Ali, Jill Lacy, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 46) with videos related to
Sort By:
Page
of 5
Molecular Cancer Therapeutics
|
November 8, 2014
Repurposing the antihelmintic mebendazole as a hedgehog inhibitor
Andrew R Larsen, Ren-Yuan Bai, Jon H Chung, et al.
JCO Precision Oncology
|
February 17, 2022
Biallelic Deletion of <i>PALB2</i> Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition
Munveer S Bhangoo, Carrie Costantini, Brian T Clifford, et al.
European Urology
|
April 25, 2018
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
Sumanta K Pal, Paulo Bergerot, Nazli Dizman, et al.
European Urology
|
September 24, 2018
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
Andrea Necchi, Patrizia Giannatempo, Daniele Raggi, et al.
The Oncologist
|
July 12, 2019
Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype
Ethan S Sokol, Dean Pavlick, Garrett M Frampton, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 22, 2020
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling
Russell Madison, Alexa B Schrock, Emily Castellanos, et al.
European Urology Focus
|
August 31, 2020
Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma
Andrea Necchi, Russell Madison, Sumanta K Pal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2021
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Jessica K Lee, Mehlika Hazar-Rethinam, Brennan Decker, et al.
Case Reports in Oncology
|
November 20, 2014
A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
Jon H Chung, Siraj M Ali, Jenni Davis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 7, 2017
Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma
Aatur D Singhi, Siraj M Ali, Jill Lacy, et al.
Page
of 5